The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1371
ISSUE1371
August 22, 2011
Rilpivirine (Edurant) - A New Drug for HIV Infection
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Rilpivirine (Edurant) - A New Drug for HIV Infection
August 22, 2011 (Issue: 1371)
The FDA has approved rilpivirine (Edurant –
Janssen), a non-nucleoside reverse transcriptase
inhibitor (NNRTI), for use with other antiretroviral
agents for treatment of HIV-1 infection in treatment-naive
adults. Rilpivirine is also available...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.